Shiyong Qi

Shiyong Qi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2025 in Advanced Science
Verified
Journal Article
Open access
SZShichao Zhang
Shichao Zhang
YXYuhan Xie
Yuhan Xie
LZLongchao Zhang
Longchao Zhang
YQYuanjiong Qi
Yuanjiong Qi
QLQuan Liao
Quan Liao
SQShiyong Qi
Shiyong Qi
Acute kidney injury (AKI) represents a critical clinical condition marked by abrupt deterioration of renal function, primarily driven by oxidative stress, inflammation, and apoptosis. However, effective targeted therapies remain limited. Here, a smart, biomimetic nanoplatform (CeAst@MK) that synergistically addresses oxidative and inflammatory injury in AKI is reported. CeAst nanoparticles are formed via coordination between Ce 3 ⁺ ions and astragalin (Ast), a natural flavonoid with intrinsic ROS‐scavenging and anti‐inflammatory properties. To enhance immune evasion and renal targeting specificity, CeAst is cloaked with macrophage membranes (MCM) and modified with a kidney‐targeting peptide (KTP), yielding the final CeAst@MK system. The platform exhibits pH‐responsive release in the acidic microenvironment of injured renal tissues, enabling precise and rapid therapeutic delivery. In both LPS‐ and ischemia reperfusion‐induced AKI models, CeAst@MK significantly improves renal function, suppresses proinflammatory cytokines, and promotes M2 macrophage polarization. Mechanistically, it modulates PI3K/Akt and NF‐κB pathways, achieving dual antioxidative and anti‐inflammatory effects. This study presents a translationally promising nanotherapeutic system integrating natural antioxidants, biomimetic camouflage, and tissue‐specific delivery, offering an effective and precise strategy for AKI intervention.

28 April 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
LZLongchao Zhang
Longchao Zhang
SYShushuai Yang
Shushuai Yang
YQYuanjiong Qi
Yuanjiong Qi
HZHaiwen Zhou
Haiwen Zhou
SZShichao Zhang
Shichao Zhang
SQShiyong Qi
Shiyong Qi
The contribution of macrophage polarization dysregulation to calcium oxalate (CaOx) nephrolithiasis remains poorly defined. Here, we identify the long non-coding RNA growth arrest-specific transcript 5 (GAS5) as a critical driver of pro-inflammatory M1 macrophage polarization through the Notch/NF-κB/NLRP3 axis, thereby aggravating CaOx-induced renal injury. In human macrophages, calcium oxalate monohydrate (COM) stimulation upregulates GAS5 expression, which functions as a competing endogenous RNA by sequestering miR-449c-5p, leading to derepression of Notch1 and amplification of downstream inflammatory signaling. Activated Notch1 engages TLR4 to trigger NF-κB/NLRP3 inflammasome activation, promoting M1 polarization, inflammatory cytokine release, tubular epithelial pyroptosis, and enhanced crystal adhesion. Given the limited conservation of lncRNA-miRNA interactions across species, we further delineated a species adaptive regulatory mechanism in mice. In murine macrophages, GAS5 enhances Notch1 signaling through sequestration of a distinct miRNA, miR-325-3p, thereby preserving the core ceRNA logic while employing different miRNA mediators. In vivo, macrophage enriched GAS5 overexpression exacerbates Gly induced CaOx deposition, renal dysfunction, and inflammation, whereas pharmacological inhibition of Notch signaling or TLR4 knockdown markedly attenuates these effects. Conversely, restoration of the corresponding regulatory miRNAs suppresses Notch1 signaling and favors anti-inflammatory macrophage polarization. Together, these findings uncover a conserved, yet species-adaptive, GAS5 centered ceRNA regulatory framework that governs macrophage driven inflammation and renal injury in CaOx nephrolithiasis, highlighting GAS5-Notch signaling as a potential immunomodulatory target for nephrolithiasis.

4 August 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
LZLongchao Zhang
Longchao Zhang
SYShushuai Yang
Shushuai Yang
YQYuanjiong Qi
Yuanjiong Qi
HZHaiwen Zhou
Haiwen Zhou
SZShichao Zhang
Shichao Zhang
SQShiyong Qi
Shiyong Qi

29 July 2026 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
SYShushuai Yang
Shushuai Yang
YQYuanjiong Qi
Yuanjiong Qi
SZShichao Zhang
Shichao Zhang
LZLongchao Zhang
Longchao Zhang
QYQiuyu Yu
Qiuyu Yu
SQShiyong Qi
Shiyong Qi
Calcium oxalate (CaOx) nephrolithiasis is a globally prevalent disease with complex pathogenesis and limited targeted therapies. The imbalance between rena

14 October 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
SZShichao Zhang
Shichao Zhang
YXYuhan Xie
Yuhan Xie
QLQuan Liao
Quan Liao
YQYuanjiong Qi
Yuanjiong Qi
SYShushuai Yang
Shushuai Yang
SQShiyong Qi
Shiyong Qi
Acute kidney injury (AKI) is a life‐threatening clinical syndrome characterized by abrupt renal dysfunction, excessive oxidative stress, inflammatory activation, and profound metabolic disturbances, yet effective therapeutic strategies remain limited. Herein, we developed an ultrasmall pH‐responsive nanoplatform (FeAst) through the self‐assembly of Fe 3+ and the natural flavonoid Astragalin (Ast) for injury‐responsive renal delivery and metabolic intervention. The Fe 3+ –phenolic coordination network endows FeAst with excellent biocompatibility, intrinsic reactive oxygen species (ROS)‐scavenging capacity, and mitochondria‐targeting capability. Importantly, FeAst preferentially accumulated in injured kidneys, enabling targeted renal delivery. Moreover, the mildly acidic microenvironment associated with AKI triggered partial dissociation of the coordination network, enabling localized Ast release and sustained therapeutic activity. Across multiple experimental models of kidney injury, FeAst markedly improved renal function, alleviated tubular injury, suppressed inflammatory responses, and restored redox homeostasis. Mechanistically, FeAst preserved mitochondrial integrity, re‐established glutathione‐dependent antioxidant defense, suppressed ferroptosis‐related processes by reducing lipid peroxidation and restoring ferroptosis defense systems, and reprogrammed TCA cycle‐associated energy metabolism. Moreover, FeAst activated PPAR signaling and suppressed p38 MAPK/NF‐κB‐mediated inflammatory responses, thereby enhancing cellular bioenergetics and resistance to oxidative stress. Collectively, this injury‐responsive nanoplatform integrates selective renal accumulation, controlled drug release, and metabolic reprogramming to provide a promising strategy for precision kidney injury therapy.

13 May 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
QLQuan Liao
Quan Liao
SZShichao Zhang
Shichao Zhang
YXYuhan Xie
Yuhan Xie
QTQidan Tan
Qidan Tan
TLTengfei Li
Tengfei Li
SQShiyong Qi
Shiyong Qi
Acute kidney injury (AKI) remains a major clinical challenge and is largely driven by excessive oxidative stress, inflammatory responses, and tubular cell apoptosis. However, effective therapeutic strategies that simultaneously target these pathological processes are still lacking. We developed a pH-responsive ultrasmall Fe-kaempferol (Fe-Kae) nanoplatform with coordinated antioxidant and anti-inflammatory activities for AKI treatment. Owing to their ultrasmall size and pH-responsive properties, Fe-Kae nanoparticles preferentially accumulated in injured renal tissues and exhibited robust renoprotective effects in multiple murine AKI models, including ischemia-reperfusion injury, cisplatin-induced nephrotoxicity, and calcium oxalate-induced kidney injury. Integrated transcriptomic and metabolomic analyses of ischemia-reperfusion-injured kidneys revealed that Fe-Kae treatment markedly enhanced efferocytosis-associated pathways and induced coordinated metabolic reprogramming, characterized by optimized tricarboxylic acid cycle activity and enhanced glutathione metabolism. This study establishes a nanomedicine-based therapeutic strategy that couples efferocytosis enhancement with metabolic reprogramming to achieve effective renoprotection. Our findings highlight pH-responsive ultrasmall metal-polyphenol nanoplatforms as a promising paradigm for the treatment of AKI.